Patricia J. Sulak
Research Subjects
Patricia J. Sulak has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
Thomas J. Kuehl
6 shared publicationsAndrea Coffee
4 shared publications- Thomas J. Kuehl
Department of Obstetrics and Gynecology, Scott & White Clinic, College Station and Temple, TX
3 shared publications Alicia L. Kuehl
2 shared publicationsBobby L. Shull
2 shared publicationsA Michael Speikermann
1 shared publication
Latest Publications
- 1 September 2008
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 112 (3) , 563-571
Frequency and Management of Breakthrough Bleeding With Continuous Use of the Transvaginal Contraceptive Ring
To assess bleeding patterns with continuous use of the transvaginal contraceptive ring. We did a prospective analysis of daily menstrual flow during a 21/7 cycle followed by 6 months of continuous use and institution of a randomized protocol to manage breakthrough bleeding/spotting. Seventy-four women completed the baseline 21/7 phase and were randomized equally into two groups during the continuous phase. Group 1 was instructed to replace the ring monthly on the same calendar day with no ring-free days. Group 2 was instructed to use the same process, but if breakthrough bleeding/spotting occurred for 5 days or more, they were to remove the ring for 4 days, store it, and then reinsert that ring. Sixty-five women completed the continuous phase with reduced average flow scores in the continuous phase compared with the 21/7 phase (P<.02). Most patients had no to minimal bleeding during continuous use, with group 2 experiencing a statistically greater percentage of days without breakthrough bleeding or spotting (95%) compared with group 1 (89%) (P=.016). Instituting a 4-day hormone-free interval was more (P<.001) effective in resolving breakthrough bleeding/spotting than continuing ring use. A reduction in bleeding occurred during continuous use with replacement of the transvaginal ring compared with baseline 21/7 use. Continuous vaginal ring use resulted in an acceptable bleeding profile in most patients, reduction in flow, reduction in pelvic pain, and a high continuation rate.
- 1 September 2008
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 112 (3) , 563-571
Frequency and Management of Breakthrough Bleeding With Continuous Use of the Transvaginal Contraceptive Ring
To assess bleeding patterns with continuous use of the transvaginal contraceptive ring. We did a prospective analysis of daily menstrual flow during a 21/7 cycle followed by 6 months of continuous use and institution of a randomized protocol to manage breakthrough bleeding/spotting. Seventy-four women completed the baseline 21/7 phase and were randomized equally into two groups during the continuous phase. Group 1 was instructed to replace the ring monthly on the same calendar day with no ring-free days. Group 2 was instructed to use the same process, but if breakthrough bleeding/spotting occurred for 5 days or more, they were to remove the ring for 4 days, store it, and then reinsert that ring. Sixty-five women completed the continuous phase with reduced average flow scores in the continuous phase compared with the 21/7 phase (P<.02). Most patients had no to minimal bleeding during continuous use, with group 2 experiencing a statistically greater percentage of days without breakthrough bleeding or spotting (95%) compared with group 1 (89%) (P=.016). Instituting a 4-day hormone-free interval was more (P<.001) effective in resolving breakthrough bleeding/spotting than continuing ring use. A reduction in bleeding occurred during continuous use with replacement of the transvaginal ring compared with baseline 21/7 use. Continuous vaginal ring use resulted in an acceptable bleeding profile in most patients, reduction in flow, reduction in pelvic pain, and a high continuation rate.
- 1 April 2008
- Vol. 53 (4) , 266-70
Pituitary-ovarian hormone levels and symptoms in oral contraceptive users: comparison of a 21/7-day and extended regimen.
To compare hormone levels and symptoms during transition from standard to extended oral contraceptive (OC) regimens. A prospective analysis of follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol, and inhibin-B levels with symptoms during 21/7-day vs. 168/7-day extended OCs containing 3 mg of drosperinone and 30 mcg of ethinyl estradiol. Blood samples were obtained from 10 subjects in each of 4 weeks in the 21/7 regimen, in the first 6 weeks of the extended regimen, and again the week before, the week of and the week after the 7-day hormone-free interval (HFI) at the end of the extended regimen. All 4 hormones followed a cyclic pattern with decreasing levels during the 3 active pill weeks of the 21/7 cycle, followed by an increase during the 7-day HFI, which continued into the extended regimen. Levels then decreased during the extended regimen and remained low at week 24. During the 7-day HFI after the extended regimen FSH and LH again increased above baseline (p > 0.07). Hormone withdrawal symptoms increased at the end of 21 active pills with increasing severity during the 7-day HFI. Absence of pituitary and ovarian suppression associated with HFI leads to fluctuations in hormones and associated hormone withdrawal symptoms.
- 1 April 2008
- Vol. 53 (4) , 266-70
Pituitary-ovarian hormone levels and symptoms in oral contraceptive users: comparison of a 21/7-day and extended regimen.
To compare hormone levels and symptoms during transition from standard to extended oral contraceptive (OC) regimens. A prospective analysis of follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol, and inhibin-B levels with symptoms during 21/7-day vs. 168/7-day extended OCs containing 3 mg of drosperinone and 30 mcg of ethinyl estradiol. Blood samples were obtained from 10 subjects in each of 4 weeks in the 21/7 regimen, in the first 6 weeks of the extended regimen, and again the week before, the week of and the week after the 7-day hormone-free interval (HFI) at the end of the extended regimen. All 4 hormones followed a cyclic pattern with decreasing levels during the 3 active pill weeks of the 21/7 cycle, followed by an increase during the 7-day HFI, which continued into the extended regimen. Levels then decreased during the extended regimen and remained low at week 24. During the 7-day HFI after the extended regimen FSH and LH again increased above baseline (p > 0.07). Hormone withdrawal symptoms increased at the end of 21 active pills with increasing severity during the 7-day HFI. Absence of pituitary and ovarian suppression associated with HFI leads to fluctuations in hormones and associated hormone withdrawal symptoms.
- 1 April 2008
- Published by Elsevier in Best Practice & Research Clinical Obstetrics & Gynaecology
- Vol. 22 (2) , 355-374
Continuous oral contraception: changing times
- 1 April 2008
- Published by Elsevier in Best Practice & Research Clinical Obstetrics & Gynaecology
- Vol. 22 (2) , 355-374
Continuous oral contraception: changing times
- 1 October 2006
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 195 (4) , 935-941
Prospective analysis of occurrence and management of breakthrough bleeding during an extended oral contraceptive regimen
- 1 October 2006
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 195 (4) , 935-941
Prospective analysis of occurrence and management of breakthrough bleeding during an extended oral contraceptive regimen
- 1 July 2006
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 195 (1) , 78-84
Impact of an adolescent sex education program that was implemented by an academic medical center
- 1 July 2006
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 195 (1) , 78-84
Impact of an adolescent sex education program that was implemented by an academic medical center
- 1 January 2006
- Published by Elsevier in Contraception
- Vol. 73 (1) , 41-45
Attitudes and prescribing preferences of health care professionals in the United States regarding use of extended-cycle oral contraceptives
- 1 January 2006
- Published by Elsevier in Contraception
- Vol. 73 (1) , 41-45
Attitudes and prescribing preferences of health care professionals in the United States regarding use of extended-cycle oral contraceptives
- 1 December 2005
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 193 (6) , 1945-1954
Analysis of knowledge and attitudes of adult groups before and after attending an educational presentation regarding adolescent sexual activity
- 1 December 2005
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 193 (6) , 1945-1954
Analysis of knowledge and attitudes of adult groups before and after attending an educational presentation regarding adolescent sexual activity
- 1 October 2004
- Published by Elsevier in Contraception
- Vol. 70 (4) , 281-287
Outcomes of extended oral contraceptive regimens with a shortened hormone-free interval to manage breakthrough bleeding
- 1 October 2004
- Published by Elsevier in Contraception
- Vol. 70 (4) , 281-287
Outcomes of extended oral contraceptive regimens with a shortened hormone-free interval to manage breakthrough bleeding
- 1 June 2002
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 186 (6) , 1142-1149
Acceptance of altering the standard 21-day/7-day oral contraceptive regimen to delay menses and reduce hormone withdrawal symptoms
- 1 June 2002
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 186 (6) , 1142-1149
Acceptance of altering the standard 21-day/7-day oral contraceptive regimen to delay menses and reduce hormone withdrawal symptoms
- Open Access
- 1 January 1997
- Published by Wiley in Infectious Diseases in Obstetrics and Gynecology
- Vol. 5 (1) , 18-22
Evaluation of 3‐day course of doxycycline for the treatment of uncomplicated Chlamydia trachomatis cervicitis
- 1 January 1997
- Published by Wiley in Infectious Diseases in Obstetrics and Gynecology
- Vol. 5 (1) , 18-22
Open AccessEvaluation of 3‐day course of doxycycline for the treatment of uncomplicated Chlamydia trachomatis cervicitis